More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$282.64B
EPS
5.04
P/E ratio
24.2
Price to sales
4.1
Dividend yield
1.165%
Beta
0.238287
Previous close
$184.02
Today's open
$181.25
Day's range
$181.08 - $183.66
52 week range
$153.41 - $212.71
show more
CEO
Pascal Soriot
Employees
94300
Headquarters
Cambridge,
Exchange
New York Stock Exchange
Shares outstanding
1.55B
Issue type
Common Stock
Healthcare
Pharmaceuticals
Allspring Large Cap Growth Fund Q3 2026 Portfolio Activity
We continue to hold Twilio stock and believe the emergence of agentic AI is expanding its addressable market. Sandisk is positioned to benefit from a growing addressable market, rising AI demand, and improved earnings visibility. With spending on data centers expected to grow significantly in the future, we believe that Vertiv remains well positioned to beat expectations and deliver strong future growth.
Seeking Alpha • 12 hours ago

AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
AZN's 16 blockbuster drugs, strong oncology sales and pipeline opportunities support its $80B revenue target, despite generic pressure and clinical setbacks.
Zacks Investment Research • Nov 17, 2026

AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
AZN secures US and EU approval for Klygefa, a once-weekly gMG treatment that offers patients greater convenience.
Zacks Investment Research • Nov 16, 2026

Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Barrons • Nov 16, 2026

AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
AstraZeneca has cut about 600 jobs from its respiratory and immunology commercial teams in the US as part of its three-year cost-savings initiative, Bloomberg News reported on Friday, citing people familiar with the matter.
Reuters • Nov 13, 2026

EU panel backs AstraZeneca hypertension drug baxdrostat
AstraZeneca said on Friday a European medicines committee had backed its hypertension pill baxdrostat, branded as Baxfendy, for marketing authorisation, potentially making it the first drug of its class to reach patients in the European Union.
Reuters • Nov 13, 2026

Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted by the Food and Drug Administration af.
Business Wire • Nov 13, 2026

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
AstraZeneca's specialty medicines in Oncology, Respiratory, and Rare Diseases are driving double-digit growth, offsetting patent cliff impacts in legacy drugs. AZN trades at a significant valuation discount: a non-GAAP FWD P/E of 18.46x and a PEG of 1.28, below sector medians, supporting a BUY rating. Q3 FY2026 saw 7% revenue growth and 4 percentage point core margin expansion, with strong pipeline momentum and 12 positive Phase III readouts.
Seeking Alpha • Nov 11, 2026

Omniose Announces Its Acquisition by AstraZeneca
ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose's proprietary bioconjugation platform and expertise into AstraZeneca, complementing existing capabilit.
Business Wire • Nov 10, 2026

AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative. The initiative supports programs that prioritize the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. Through the 6th annual Community Solutions Challenge (CSC), ACT on Health Equity supports nonprofit programs focused on advancing health.
Business Wire • Nov 10, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AstraZeneca PLC commission-free¹. Build wealth for the long term using automated trading and transfers.